Wednesday, 23 May 2018

Mylan launches generic version of Oral Contraceptive Yaz

26 April 2018 | News

FDA approved this product to help women manage their health across all the stages of their lives.

Global pharmaceutical company Mylan announced the U.S. launch of Drospirenone and Ethinyl Estradiol Tablets USP, 3 mg/0.02 mg, a generic version of Bayer's Yaz® Tablets.

Mylan Pharmaceuticals received final approval from the U.S. Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA) for this product, which is indicated for use by women to prevent pregnancy and for the treatment of acne vulgaris in women at least 14 years of age who have achieved menarche and desire an oral contraceptive for birth control.

 

In the U.S., Mylan offers more than 20 generic birth control medicines in multiple dosage forms. The products are a part of Mylan's growing U.S. women's healthcare portfolio, which includes a vast suite of medicines to help women manage their health across all the stages of their lives.

 

Women over 35 years old who smoke should not use Drospirenone and Ethinyl Estradiol Tablets USP, 3 mg/0.02 mg. Cigarette smoking increases the risk of serious cardiovascular events from combination oral contraceptive use.

 

Comments

× Your session has been expired. Please click here to Sign-in or Sign-up
   New User? Create Account





Survey Box

Does India need to talk about Mental Health?

× Please select an option to participate in the poll.
Processing...   View poll results   More polls

× You have successfully cast your vote.
{{ optionDetail.option }}{{ optionDetail.percentage }}%
{{ optionDetail.percentage }}% Complete
More polls